Pharvaris (NASDAQ:PHVS) Sets New 12-Month Low – Here’s Why

Pharvaris (NASDAQ:PHVS) shares reached a new 52-week low during trading on Thursday . The stock traded as low as $14.50 and last traded at $14.99, with a volume of 152659 shares. The stock had previously closed at $15.45.

Analyst Upgrades and Downgrades

Separately, JMP Securities upped their price objective on shares of Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, January 31st.

Pharvaris Price Performance

The company has a market cap of $783.83 million, a PE ratio of -5.35 and a beta of -3.02. The stock’s 50-day moving average is $17.57 and its 200 day moving average is $19.24.

Institutional Trading of Pharvaris

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC purchased a new stake in Pharvaris in the third quarter valued at about $526,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Pharvaris in the 3rd quarter valued at approximately $906,000. State Street Corp acquired a new stake in Pharvaris in the 3rd quarter worth approximately $1,000,000. Geode Capital Management LLC grew its position in Pharvaris by 18.4% during the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock worth $685,000 after purchasing an additional 5,753 shares during the last quarter. Finally, Barclays PLC acquired a new position in Pharvaris during the 3rd quarter valued at approximately $106,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.